CY1125577T1 - Αντισωματα κατα της muc16 (βλεννινης 16) - Google Patents

Αντισωματα κατα της muc16 (βλεννινης 16)

Info

Publication number
CY1125577T1
CY1125577T1 CY20221100635T CY221100635T CY1125577T1 CY 1125577 T1 CY1125577 T1 CY 1125577T1 CY 20221100635 T CY20221100635 T CY 20221100635T CY 221100635 T CY221100635 T CY 221100635T CY 1125577 T1 CY1125577 T1 CY 1125577T1
Authority
CY
Cyprus
Prior art keywords
muc16
antigen binding
antibodies
present
useful
Prior art date
Application number
CY20221100635T
Other languages
English (en)
Inventor
Lauric Haber
Eric Smith
Marcus KELLY
Jessica R. Kirshner
Sandra COETZEE
Alison CRAWFORD
Thomas Nittoli
Yashu Liu
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1125577T1 publication Critical patent/CY1125577T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η βλεννίνη 16 (MUC16) εκφράζεται σε μεγάλο βαθμό στον καρκίνο των ωοθηκών και η έκφραση σε καρκινικά κύτταρα φαίνεται ότι προστατεύει τα κύτταρα όγκου από το ανοσοποιητικό σύστημα. η παρούσα εφεύρεση παρέχει καινοφανή πλήρους μήκους ανθρώπινα αντισώματα IgG που δεσμεύονται με ανθρώπινα και MUC16 (μονοειδικά αντισώματα). Η παρούσα εφεύρεση παρέχει επίσης καινοφανή αμφιειδικά αντισώματα (bsABs) που δεσμεύονται τόσο με τη MUC16 όσο και το CD3 και ενεργοποιούν τα Τ κύτταρα μέσο του συμπλόκου CD3 παρουσία όγκων που εκφράζουν MUC16. Σύμφωνα με ορισμένους τρόπους υλοποίησης, η παρούσα εφεύρεση παρέχει αμφιειδικά μόρια δέσμευσης αντιγόνου που περιλαμβάνουν έναν πρώτο τομέα δέσμευσης αντιγόνου που δεσμεύει ειδικά CD3 ανθρώπου και πιθήκου, και ένα δεύτερο μόριο δέσμευσης αντιγόνου που δεσμεύει ειδικά MUC16 ανθρώπου και πιθήκου. Σε ορισμένους τρόπους υλοποίησης, τα αμφιειδικά μόρια δέσμευσης αντιγόνου της παρούσας εφεύρεσης έχουν την ικανότητα αναστολής της ανάπτυξης όγκων που εκφράζουν τη MUC16. Τα αμφιειδικά μόρια δέσμευσης αντιγόνου της εφεύρεσης είναι χρήσιμα στη θεραπευτική αντιμετώπιση ασθενειών και διαταραχών όπου μια αυξορρυθμισμένη ή επαγόμενη ανοσοαπόκριση που στοχεύει την MUC16 είναι επιθυμητή και/ή θεραπευτικά επωφελής. Για παράδειγμα, τα αμφιειδικά αντισώματα της εφεύρεσης είναι χρήσιμα για τη θεραπευτική αντιμετώπιση διάφορων καρκίνων. συμπεριλαμβανομένου του καρκίνου των ωοθηκών. Η παρούσα εφεύρεση περιλαμβάνει επίσης συζεύγματα φαρμάκου αντισώματος αντι-MUC16 που αναστέλλουν την ανάπτυξη όγκου in vivo. Σε μερικούς τρόπους υλοποίησης, τα αντισώματα αντι-MUC16 είναι χρήσιμα σε διαγνωστικές μεθόδους για τον εντοπισμό της παρουσίας της MUC16 σε δείγματα ιστού και/ή πλάσματος.
CY20221100635T 2016-09-23 2022-09-27 Αντισωματα κατα της muc16 (βλεννινης 16) CY1125577T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662399249P 2016-09-23 2016-09-23
US201762558711P 2017-09-14 2017-09-14

Publications (1)

Publication Number Publication Date
CY1125577T1 true CY1125577T1 (el) 2026-02-25

Family

ID=60083442

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100635T CY1125577T1 (el) 2016-09-23 2022-09-27 Αντισωματα κατα της muc16 (βλεννινης 16)

Country Status (29)

Country Link
US (4) US10941208B2 (el)
EP (3) EP3515487B1 (el)
JP (2) JP7066690B2 (el)
KR (2) KR102531251B1 (el)
CN (2) CN110214026B (el)
AU (2) AU2017339711B2 (el)
BR (2) BR112019005670A2 (el)
CA (3) CA3037536C (el)
CL (4) CL2019000712A1 (el)
CO (1) CO2019003967A2 (el)
CY (1) CY1125577T1 (el)
DK (2) DK3515487T5 (el)
ES (2) ES2925563T3 (el)
FI (1) FI3515487T3 (el)
HR (2) HRP20221202T1 (el)
HU (2) HUE063020T2 (el)
IL (2) IL265309B2 (el)
LT (2) LT3515946T (el)
MD (1) MD3515487T2 (el)
MX (2) MX2019003326A (el)
MY (2) MY194596A (el)
PH (2) PH12019500550A1 (el)
PL (2) PL3515946T3 (el)
PT (2) PT3515487T (el)
RS (2) RS64691B1 (el)
SI (2) SI3515487T1 (el)
SM (2) SMT202300308T1 (el)
WO (2) WO2018058003A1 (el)
ZA (2) ZA201901557B (el)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
AU2016325630B2 (en) * 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
EA201891753A1 (ru) 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
EA201991673A1 (ru) * 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
RU2747095C2 (ru) * 2018-05-11 2021-04-26 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125
CN108659131B (zh) * 2018-05-28 2021-09-14 长春力太生物技术有限公司 一种抗ceacam-5的单域抗体及其应用
TW202504917A (zh) * 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
IL279354B1 (en) 2018-06-21 2026-02-01 Regeneron Pharma Bispecific antibodies against psma and against cd28 and their uses
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MD3823665T2 (ro) 2018-07-19 2024-05-31 Regeneron Pharma Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
CA3109513A1 (en) 2018-08-23 2020-02-27 Regeneron Pharmaceuticals, Inc. Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
JP2022514122A (ja) 2018-10-31 2022-02-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質を同定及び定量化する方法及びシステム
CN113366022B (zh) 2018-11-16 2025-11-21 纪念斯隆凯特琳癌症中心 针对粘蛋白-16的抗体及其使用方法
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
MA54540A (fr) 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
US11453721B2 (en) 2018-12-19 2022-09-27 Regeneran Pharmaceuticals, Inc. Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
CA3134335A1 (en) 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
EP3986934A1 (en) * 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
WO2021005607A1 (en) * 2019-07-09 2021-01-14 National Institute For Biotechnology In The Negev Ltd. Antibodies with reduced immunogenicity
US12077603B2 (en) 2019-08-15 2024-09-03 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules for cell targeting and uses thereof
CN112969715B (zh) * 2019-08-21 2022-03-18 和铂医药(上海)有限责任公司 一种抗cd47抗原结合蛋白及其应用
UA130408C2 (uk) * 2019-09-06 2026-02-11 Ле Лаборатуар Сервьє Антитіла до cd73
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
US11814428B2 (en) * 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
CN114929343B (zh) * 2019-12-06 2025-03-18 瑞泽恩制药公司 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
EP4267722A1 (en) * 2020-12-22 2023-11-01 Amgen Inc. Diffusion gradient assay for anti-cd3-containing molecules
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
TW202304507A (zh) 2021-04-02 2023-02-01 美商再生元醫藥公司 含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物
JP2024523033A (ja) 2021-06-17 2024-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の三重特異的結合分子
EP4437003A1 (en) 2021-11-24 2024-10-02 Regeneron Pharmaceuticals, Inc. Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
US20230312718A1 (en) 2022-01-07 2023-10-05 Regeneron Pharmaceuticals, Inc Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies
JP2025504795A (ja) * 2022-01-10 2025-02-19 ナンチン リーズ バイオラブス カンパニー，リミティド 抗体及びその用途
JP2025504398A (ja) * 2022-01-10 2025-02-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｍｕｃ１６キメラ抗原受容体
IL315405A (en) 2022-03-17 2024-11-01 Regeneron Pharma Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2024051752A1 (en) * 2022-09-06 2024-03-14 I-Mab Biopharma Co., Ltd. Multispecific constructs and uses thereof
WO2024123698A1 (en) 2022-12-08 2024-06-13 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞
IL323074A (en) 2023-03-13 2025-10-01 Regeneron Pharma Methods for treating cancer with anti-CD22 x anti-CD28 bispecific molecules
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
WO2025014913A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1xcd28 antibodies and methods of use thereof
CN121666401A (zh) 2023-07-10 2026-03-13 瑞泽恩制药公司 双特异性PD-L1x4-1BB抗体及其使用方法
IL326412A (en) 2023-08-11 2026-04-01 Wuxi Biologics Ireland Ltd Anti-muc16 antibodies and uses thereof
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
US20250114469A1 (en) 2023-10-09 2025-04-10 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE
CN119978126A (zh) * 2023-11-10 2025-05-13 深圳市菲鹏生物治疗股份有限公司 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用
TW202523694A (zh) * 2023-11-17 2025-06-16 中國大陸商上海藥明生物技術有限公司 抗muc16抗體及其用途
TW202539732A (zh) 2023-11-29 2025-10-16 美商再生元醫藥公司 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
TW202542187A (zh) 2023-12-12 2025-11-01 美商再生元醫藥公司 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法
WO2026015612A1 (en) 2024-07-10 2026-01-15 Regeneron Pharmaceuticals, Inc. Methods of treating smarcb1-deficient cancers
WO2026050255A2 (en) 2024-08-27 2026-03-05 Regeneron Pharmaceuticals, Inc. Anti-slc3a2-apis antigen-binding proteins and methods of use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
CA2443617C (en) 2001-04-17 2013-12-10 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
ATE293794T1 (de) 2001-12-04 2005-05-15 Brahms Ag Verfahren zur diagnose von sepsis unter bestimmung von ca 125
WO2004035537A2 (en) 2002-10-16 2004-04-29 Euro-Celtique S.A. Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
DK1629011T3 (da) 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
CL2008001334A1 (es) * 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US8187801B2 (en) 2008-04-24 2012-05-29 Wisconsin Alumni Research Foundation Methods and kits to detect and monitor ovarian cancer and preeclampsia
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
CA3255551A1 (en) 2010-03-26 2025-04-15 Memorial Sloan-Kettering Cancer Center MUC16 ANTIBODIES AND METHODS OF USE
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
WO2012070029A1 (en) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A pharmaceutical composition
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
BR112014009070B1 (pt) 2011-10-14 2021-11-23 Medimmune Limited Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
JP6847388B2 (ja) 2013-03-15 2021-03-31 レゲネロン ファーマシューティカルス，インコーポレーテッド 生物活性分子、そのコンジュゲート、及び治療用途
BR112016004023A2 (pt) 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
IL263466B2 (en) * 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
TWI701042B (zh) * 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX375669B (es) * 2014-09-26 2025-03-06 Macrogenics Inc Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos.
SG11201707538XA (en) * 2015-03-17 2017-10-30 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
BR112017020149A8 (pt) 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
JP7066690B2 (ja) * 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
EP3986934A1 (en) * 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
TW202304507A (zh) * 2021-04-02 2023-02-01 美商再生元醫藥公司 含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物
EP4437003A1 (en) * 2021-11-24 2024-10-02 Regeneron Pharmaceuticals, Inc. Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
US20230312718A1 (en) * 2022-01-07 2023-10-05 Regeneron Pharmaceuticals, Inc Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies

Also Published As

Publication number Publication date
HRP20231281T1 (hr) 2024-02-02
ZA201901557B (en) 2024-08-28
BR112019005697A2 (pt) 2019-07-16
KR20190073377A (ko) 2019-06-26
DK3515946T5 (da) 2024-09-02
HUE059761T2 (hu) 2022-12-28
US11485793B2 (en) 2022-11-01
US20230272111A1 (en) 2023-08-31
WO2018067331A9 (en) 2018-06-07
US20180112001A1 (en) 2018-04-26
JP7066690B2 (ja) 2022-05-13
CN110214026B (zh) 2023-12-05
DK3515946T3 (en) 2022-08-01
SMT202300308T1 (it) 2023-11-13
NZ751903A (en) 2025-09-26
ES2925563T3 (es) 2022-10-18
SI3515946T1 (sl) 2022-09-30
EP3515487A1 (en) 2019-07-31
CA3037536C (en) 2026-02-17
DK3515487T3 (da) 2023-08-28
MX2019003322A (es) 2019-08-05
AU2017339711B2 (en) 2024-06-06
CL2019000712A1 (es) 2019-05-31
CO2019003967A2 (es) 2019-05-10
LT3515946T (lt) 2022-08-10
CA3287248A1 (en) 2026-03-02
JP2019536740A (ja) 2019-12-19
AU2017331363B2 (en) 2024-06-13
RS63660B1 (sr) 2022-11-30
PH12019500604A1 (en) 2019-06-03
HUE063020T2 (hu) 2023-12-28
PH12019500550A1 (en) 2019-05-27
JP7066691B2 (ja) 2022-05-13
IL265309A (en) 2019-05-30
HRP20221202T1 (hr) 2022-12-09
EP4273172A3 (en) 2024-02-28
EP3515487B1 (en) 2023-07-19
RS64691B1 (sr) 2023-11-30
BR112019005670A2 (pt) 2019-06-04
CL2023002690A1 (es) 2024-02-02
NZ751907A (en) 2025-09-26
IL265369B1 (en) 2023-11-01
WO2018058003A1 (en) 2018-03-29
KR102531251B1 (ko) 2023-05-15
MX2019003326A (es) 2019-09-10
US10738130B2 (en) 2020-08-11
CN110214026A (zh) 2019-09-06
IL265309B2 (en) 2024-04-01
MY200230A (en) 2023-12-15
CL2019000726A1 (es) 2019-05-31
DK3515487T5 (da) 2024-09-02
FI3515487T3 (fi) 2023-08-15
ZA201901591B (en) 2024-05-30
ES2952735T3 (es) 2023-11-03
PL3515487T3 (pl) 2024-01-15
CL2021002645A1 (es) 2022-04-29
EP4273172A2 (en) 2023-11-08
PL3515946T3 (pl) 2022-11-07
MD3515487T2 (ro) 2023-11-30
US10941208B2 (en) 2021-03-09
US12570764B2 (en) 2026-03-10
MY194596A (en) 2022-12-06
IL265309B1 (en) 2023-12-01
KR102418667B1 (ko) 2022-07-12
US20180118848A1 (en) 2018-05-03
PT3515487T (pt) 2023-08-24
JP2019533807A (ja) 2019-11-21
IL265369A (en) 2019-05-30
EP3515946A1 (en) 2019-07-31
EP3515946B1 (en) 2022-07-06
LT3515487T (lt) 2023-08-25
AU2017331363A1 (en) 2019-04-11
US20200317810A1 (en) 2020-10-08
SMT202200359T1 (it) 2022-11-18
SI3515487T1 (sl) 2023-09-29
CA3037536A1 (en) 2018-03-29
WO2018067331A1 (en) 2018-04-12
CN110036032A (zh) 2019-07-19
CN110036032B (zh) 2023-09-05
KR20190067808A (ko) 2019-06-17
CA3037738A1 (en) 2018-04-12
PT3515946T (pt) 2022-08-04
AU2017339711A1 (en) 2019-04-11
IL265369B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
CY1125577T1 (el) Αντισωματα κατα της muc16 (βλεννινης 16)
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
CY1124944T1 (el) Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων
JOP20200237B1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
MX2025005515A (es) Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
CY1121648T1 (el) ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΠΡΟΣ ΠΡΟΓΡΑΜΜΑΤΙΣΜΕΝΟ ΘΑΝΑΤΟ l(PD-l) ΚΑΙ ΜΕΘΟΔΟΙ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΡΚΙΝΟΥ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ANTI-PD-1 ΑΝΤΙΣΩΜΑΤΑ ΜΟΝΑ Ή ΣΕ ΣΥΝΔΥΑΣΜΟ ΜΕ ΑΛΛΕΣ ΑΝΟΣΟΘΕΡΑΠΕΥΤΙΚΕΣ
EA201691858A1 (ru) Композиции антител для лечения опухолей
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
ZA202006504B (en) Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
CY1119430T1 (el) Anti-s100a7 αντισωματα για τη θεραπευτικη αγωγη και διαγνωση καρκινου
EA201990779A1 (ru) Биспецифичные анти-muc16-cd3 антитела и конъюгаты анти-muc16-лекарственное средство
TH1901001723A (th) แอนติ-muc16 แอนติบอดี, คอยจูเกตของแอนติบอดี-ยา, และโมเลกุลที่จับกับไบสเปซิฟิกแอนติเจนที่ซึ่งจับ muc16 และ cd3, และการใช้พวกมัน
EA201991227A1 (ru) Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения
EA202090303A2 (ru) Композиции антител для лечения опухолей